482 completed, 34 terminated, 32 recruiting, 28 unknown. 616 Phase 3, 49 Phase 2.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 3 | 616 | Completed 482, Terminated 34, Recruiting 32, Unknown 28, Withdrawn 22, Active not recruiting 10, Not yet recruiting 6, Enrolling by invitation 1, Suspended 1 |
| Phase 2 | 49 | Completed 33, Unknown 8, Withdrawn 4, Active not recruiting 3, Terminated 1 |
Follow Asthma: new trials by email Literature Review of Asthma trials Research Report on Asthma
Trials (filtered) newest first · largest first
All 616 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma
CHF5993 100/6/12.5 μg pMDI HFA-152a, Seretide Evohaler - Asthma | Phase 3 | Not yet recruiting | 700 | 2026-11-16 | 2026-10-05 |
An Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Budesonide/Formoterol Fumarate in Participants Aged 4 to Less Than 12 Years of Age With Moderate Persistent Asthma
BFF MDI, BD MDI - Asthma | Phase 3 | Not yet recruiting | 216 | 2026-10-30 | 2026-11-13 |
Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)
N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma | Phase 3 | Withdrawn | | 2026-10-01 | 2026-10-23 |
A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma
tilrekimig, Placebo - Asthma | Phase 3 | Recruiting | 1100 | 2026-09-30 | 2026-11-05 |
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
HFA-152a, HFA-134a - Asthma | Phase 3 | Recruiting | 110 | 2026-09-01 | 2026-11-05 |
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)
GSK5784283, Placebo, Standard of care - Asthma | Phase 3 | Recruiting | 514 | 2026-08-27 | 2026-09-25 |
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)
GSK5784283, Placebo, Standard of care - Asthma | Phase 3 | Recruiting | 370 | 2026-08-27 | 2026-11-12 |
A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma
tilrekimig, Placebo - Asthma | Phase 3 | Recruiting | 1100 | 2026-08-20 | 2026-10-30 |
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149 - Asthma | Phase 3 | Recruiting | 188 | 2026-08-04 | 2026-11-10 |
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | 230 | 2026-07-24 | 2026-11-13 |
Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists
Experimental: Participant Group CHF 5993 pMDI HFA-152a, Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a - Asthma | Phase 3 | Recruiting | 554 | 2026-06-26 | 2026-07-08 |
A Study of Depemokimab in Participants of 6 to 11 Years of Age
Depemokimab - Asthma | Phase 3 | Recruiting | 34 | 2026-06-25 | 2026-08-26 |
Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma
Beclometasone Dipropionate and Formoterol Inhalation Aerosol, FOSTER® - Asthma (Diagnosis) | Phase 3 | Recruiting | 416 | 2026-06-08 | 2026-08-17 |
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
Depemokimab, Placebo - Asthma | Phase 3 | Recruiting | 456 | 2026-03-13 | 2026-08-17 |
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Dupilumab Prefilled Syringe, Placebo Injection - Asthma Control | Phase 3 | Recruiting | 150 | 2026-01-29 | 2026-11-06 |
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Tezepelumab - Severe Asthma | Phase 3 | Recruiting | 400 | 2026-01-28 | 2026-11-04 |
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
GB-0895, Placebo - Severe Asthma | Phase 3 | Recruiting | 786 | 2026-01-20 | 2026-11-03 |
Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma
tezepelumab (Arm1&Arm2) - Asthma | Phase 3 | Not yet recruiting | 636 | 2025-12-25 | 2025-12-24 |
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
GB-0895, Placebo - Severe Asthma | Phase 3 | Recruiting | 786 | 2025-12-03 | 2026-11-13 |
Magnesium Trial in Acute Asthma in Emergency Department
magnesium sulfate, Normal Saline - Asthma | Phase 3 | Recruiting | 192 | 2025-10-08 | 2025-12-18 |
Showing 20 of 616. Sign in to see all of them.
Narrower conditions
Lung Diseases (24) · Lung Diseases, Obstructive (18) · Respiratory Tract Diseases (16) · Bronchial Diseases (15) · Hypersensitivity (15) · Pulmonary Eosinophilia (12) · Asthma, Exercise-Induced (11) · Pulmonary Disease, Chronic Obstructive (10) · Respiratory Sounds (9) · Rhinitis, Allergic (9) · Dyspnea (8) · Inflammation (7) · Bronchial Spasm (6) · Respiratory Hypersensitivity (5)
Broader conditions
Hypersensitivity, Immediate (615) · Immune System Diseases (613) · Respiratory Hypersensitivity (611) · Bronchial Diseases (601) · Hypersensitivity (601) · Respiratory Tract Diseases (600) · Lung Diseases, Obstructive (588) · Lung Diseases (582) · Pathological Conditions, Signs and Symptoms (50) · Pathologic Processes (24) · Otorhinolaryngologic Diseases (22) · Signs and Symptoms (21) · Nose Diseases (19) · Hemic and Lymphatic Diseases (18) · Signs and Symptoms, Respiratory (17)
Interventions
Budesonide (75) · Fluticasone (50) · Albuterol (49) · Budesonide, Formoterol Fumarate Drug Combination (48) · Formoterol Fumarate (42) · montelukast (40) · Beclomethasone (31) · Salmeterol Xinafoate (28) · Fluticasone-Salmeterol Drug Combination (25) · ciclesonide (25) · benralizumab (22) · Omalizumab (20) · fluticasone furoate (18) · tezepelumab (16) · Mometasone Furoate (11)
Sponsors
AstraZeneca (119) · GlaxoSmithKline (61) · Organon and Co (37) · Teva Branded Pharmaceutical Products R&D, Inc. (23) · Chiesi Farmaceutici S.p.A. (22) · Novartis Pharmaceuticals (22) · Boehringer Ingelheim (17) · Milton S. Hershey Medical Center (17) · Sanofi (16) · Sumitomo Pharma America, Inc. (10) · Amphastar Pharmaceuticals, Inc. (7) · Novartis (7) · Mundipharma Research Limited (6) · SkyePharma AG (6) · Eurofarma Laboratorios S.A. (5)
Countries
United States (271) · Germany (115) · Poland (112) · Canada (105) · Argentina (82) · Russia (81) · Spain (81) · United Kingdom (81) · Hungary (75) · France (72) · Ukraine (71) · Japan (69) · Italy (66) · Mexico (66) · South Africa (57)
Top investigators
Catherine Bonuccelli (11) · Elliot Israel, MD (6) · David T. Mauger, PhD (4) · Mario Castro, MD (4)
Results publications
PMID 36472162, PMID 27881132, PMID 31319851, PMID 39393433, PMID 29174062, PMID 30954640, PMID 32180164, PMID 22329608, PMID 24966061, PMID 26369589, PMID 26498386, PMID 26612545, PMID 26704701, PMID 29536781, PMID 30802500, PMID 31047111, PMID 31251094, PMID 31447130, PMID 31760132, PMID 33217063, PMID 33223095, PMID 34098955, PMID 35287231, PMID 35636689, PMID 36356712, PMID 36702146, PMID 19995138, PMID 20075384, PMID 20835586, PMID 22938706, PMID 24314123, PMID 24838406, PMID 25682232, PMID 25724847, PMID 27087007, PMID 27216137, PMID 27616196, PMID 27912982, PMID 28069068, PMID 28624608, PMID 29409951, PMID 29949045, PMID 30077185, PMID 30139780, PMID 31507641, PMID 31579676, PMID 31582314, PMID 31626906, PMID 31654891, PMID 31803473
NIH funding
2015 (12), 2016 (11), 2023 (10), 2009 (8), 2017 (8), U10HL098115 (7), 2014 (5), U10HL074073 (5), U10HL074204 (5), U10HL074208 (5), U10HL074212 (5), U10HL074218 (5), U10HL074225 (5), U10HL074227 (5), U10HL074231 (5)